Market News & Trends
Record Number of Medicines for Rare Diseases Recommended for Approval in 2014
In 2014, the European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing authorisation in a year. Out of the 82…
Recently Discovered Super-Antibiotic Hailed as a Game-Changer
By: Anna Azvolinsky | January 7, 2015 | The Scientist Many of the most widely used antibiotics have come out of the dirt. Penicillin…
Roche to Acquire Dutalys to Augment Development Pipeline
Roche recently announced it has agreed to acquire Dutalys GmbH, which specializes in the discovery and development of fully human, bi-specific antibodies based on its…
Phylogica Enters Research & Licensing Agreement With Genentech
Phylogica Ltd. recently announced it has extended its collaboration with Genentech, a member of the Roche Group, by entering into a Research and Licensing agreement…
Achillion Shows Potential for Best-in-Disease Regimen
Achillion Pharmaceuticals, Inc. recently announced positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors,…
ARIAD & Otsuka Announce Co-Development & Commercialization Agreement
ARIAD Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. recently announced they have entered into an agreement for Otsuka to commercialize ARIAD’s Iclusig (ponatinib) in Japan…
Actavis Confirms Receipt of Complete Response Letter
Actavis plc recently confirmed it has received a complete response letter from the US FDA for its New Drug Application (NDA) for the fixed-dose combination…
Gilead Announces Amended Agreements With Janssen
Gilead Sciences, Inc. recently announced an expansion to its agreement with Janssen R&D Ireland for the development and commercialization of a new once-daily single tablet…
Roche to Enter the Genomic Informatics Market
Roche recently announced the acquisition of Bina Technologies, Inc. (Bina), a privately held company based in Redwood City, California, USA. Bina provides a big data…
FUJIFILM Completes Acquisition of Biotherapeutics Company
FUJIFILM Diosynth Biotechnologies U.S.A. Inc. (FDBU), a FUJIFILM Corporation subsidiary, recently announced the completion of its acquisition of Kalon Biotherapeutics LLC, marking an important new chapter…
Insys Therapeutics Receives FDA Orphan Drug Designation
Insys Therapeutics, Inc. recently announced that the US FDA has granted orphan drug designation (ODD) to its Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) candidate…
Unilife Signs Long-Term Commercial Supply Agreement for Use of Depot-jectTM Delivery System
Unilife Corporation recently announced the signing of a worldwide 10-year Commercial Supply Agreement with a global pharmaceutical company for the use of the Depot-jectTM delivery…
Juno Therapeutics Raises IPO Target to $191 Million
Seattle cancer-immunotherapy company Juno Therapeutics recently announced it has upped the target for its pending initial public offering of stock and gave the first indication…
iTeos Therapeutics Announces License & Collaboration With Pfizer
iTeos Therapeutics SA recently announced a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos’ preclinical compounds targeting…
Lightlake Therapeutics Announces Licensing Deal With Adapt Pharma Limited Subsidiary
LONDON, Dec. 16, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, recently…
Merck to Acquire Global Biopharmaceutical Company for Billions
Merck and Cubist Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share…
Hemispherx’s Ampligen Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
Philadelphia, PA, December 16, 2014: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”), recently announced further progress on developing Ampligen® (rintatolimod) as a potential…
Angiochem Publishes Data for Treatment of Brain Metastases
Angiochem recently announced that ANG4043, a peptide-monoclonal antibody (mAb) conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. The antibody…
Norwich Pharma Services Refines Business Strategy
Norwich, New York – December 16, 2014 – Norwich Pharma Services, a provider of contract manufacturing and clinical research services for the pharmaceutical industry, announced…
Top 30 Pharma Companies Spent $112 Billion on Research & Development in 2013
LONDON, UK (GlobalData), 16 December 2014 - The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013,…
